These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34518197)

  • 1. Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade.
    Aaboe Jørgensen M; Ugel S; Linder Hübbe M; Carretta M; Perez-Penco M; Weis-Banke SE; Martinenaite E; Kopp K; Chapellier M; Adamo A; De Sanctis F; Frusteri C; Iezzi M; Zocca MB; Hargbøll Madsen D; Wakatsuki Pedersen A; Bronte V; Andersen MH
    Cancer Immunol Res; 2021 Nov; 9(11):1316-1326. PubMed ID: 34518197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
    Steggerda SM; Bennett MK; Chen J; Emberley E; Huang T; Janes JR; Li W; MacKinnon AL; Makkouk A; Marguier G; Murray PJ; Neou S; Pan A; Parlati F; Rodriguez MLM; Van de Velde LA; Wang T; Works M; Zhang J; Zhang W; Gross MI
    J Immunother Cancer; 2017 Dec; 5(1):101. PubMed ID: 29254508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment.
    Su X; Xu Y; Fox GC; Xiang J; Kwakwa KA; Davis JL; Belle JI; Lee WC; Wong WH; Fontana F; Hernandez-Aya LF; Kobayashi T; Tomasson HM; Su J; Bakewell SJ; Stewart SA; Egbulefu C; Karmakar P; Meyer MA; Veis DJ; DeNardo DG; Lanza GM; Achilefu S; Weilbaecher KN
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34520398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Oral Arginase 1/2 Inhibitor Enhances the Antitumor Effect of PD-1 Inhibition in Murine Experimental Gliomas by Altering the Immunosuppressive Environment.
    Pilanc P; Wojnicki K; Roura AJ; Cyranowski S; Ellert-Miklaszewska A; Ochocka N; Gielniewski B; Grzybowski MM; Błaszczyk R; Stańczak PS; Dobrzański P; Kaminska B
    Front Oncol; 2021; 11():703465. PubMed ID: 34504786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells.
    Glöckner HJ; Martinenaite E; Landkildehus Lisle T; Grauslund J; Ahmad S; Met Ö; Thor Straten P; Hald Andersen M
    Oncoimmunology; 2024; 13(1):2318053. PubMed ID: 38404966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.
    Grauslund JH; Holmström MO; Martinenaite E; Lisle TL; Glöckner HJ; El Fassi D; Klausen U; Mortensen REJ; Jørgensen N; Kjær L; Skov V; Svane IM; Hasselbalch HC; Andersen MH
    Front Immunol; 2023; 14():1117466. PubMed ID: 36911725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
    Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
    J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
    J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arginase 1 is a key driver of immune suppression in pancreatic cancer.
    Menjivar RE; Nwosu ZC; Du W; Donahue KL; Hong HS; Espinoza C; Brown K; Velez-Delgado A; Yan W; Lima F; Bischoff A; Kadiyala P; Salas-Escabillas D; Crawford HC; Bednar F; Carpenter E; Zhang Y; Halbrook CJ; Lyssiotis CA; Pasca di Magliano M
    Elife; 2023 Feb; 12():. PubMed ID: 36727849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of NET-associated human ARG1 enhances cancer immunotherapy.
    Canè S; Barouni RM; Fabbi M; Cuozzo J; Fracasso G; Adamo A; Ugel S; Trovato R; De Sanctis F; Giacca M; Lawlor R; Scarpa A; Rusev B; Lionetto G; Paiella S; Salvia R; Bassi C; Mandruzzato S; Ferrini S; Bronte V
    Sci Transl Med; 2023 Mar; 15(687):eabq6221. PubMed ID: 36921034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8
    Zhang Md J; Zhang Md L; Yang Md Y; Liu Md Q; Ma Md H; Huang Md A; Zhao Md Y; Xia Md Z; Liu Md T; Wu Md G
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1533-1546. PubMed ID: 33238192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
    Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
    Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma.
    Sosnowska A; Chlebowska-Tuz J; Matryba P; Pilch Z; Greig A; Wolny A; Grzywa TM; Rydzynska Z; Sokolowska O; Rygiel TP; Grzybowski M; Stanczak P; Blaszczyk R; Nowis D; Golab J
    Oncoimmunology; 2021; 10(1):1956143. PubMed ID: 34367736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.
    Miret JJ; Kirschmeier P; Koyama S; Zhu M; Li YY; Naito Y; Wu M; Malladi VS; Huang W; Walker W; Palakurthi S; Dranoff G; Hammerman PS; Pecot CV; Wong KK; Akbay EA
    J Immunother Cancer; 2019 Feb; 7(1):32. PubMed ID: 30728077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial.
    Lorentzen CL; Martinenaite E; Kjeldsen JW; Holmstroem RB; Mørk SK; Pedersen AW; Ehrnrooth E; Andersen MH; Svane IM
    Front Immunol; 2022; 13():1023023. PubMed ID: 36330525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.
    Clavijo PE; Friedman J; Robbins Y; Moore EC; Smith E; Zauderer M; Evans EE; Allen CT
    Cancer Immunol Res; 2019 Feb; 7(2):282-291. PubMed ID: 30514791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.